Gelonghui, October 11 | Today, Kelun Biotech's antibody-drug conjugate (ADC) targeting human trophoblast cell surface antigen 2 (TROP2), Luskansatuzumab (brand name: Jiatailai), received approval from the National Medical Products Administration for its third indication. It is intended for the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who are positive for EGFR gene mutations and have progressed after treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs).
Kelun-Biotech's ADC Drug Receives Approval for Third Indication
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Market Insights
HK Tech and Internet Stocks HK Tech and Internet Stocks
Stocks of companies primarily involved in technology and internet sectors in the HK stock market. Stocks of companies primarily involved in technology and internet sectors in the HK stock market.
View More
Nancy Pelosi Portfolio Nancy Pelosi Portfolio
Former U.S. House Speaker Pelosi, renowned as the "Stock Market Queen" in politics, concentrates her investment portfolio on tech giants in AI and semiconductors. Her core strategy involves purchasing call options for leveraged trading to maximize potential returns. Former U.S. House Speaker Pelosi, renowned as the "Stock Market Queen" in politics, concentrates her investment portfolio on tech giants in AI and semiconductors. Her core strategy involves purchasing call options for leveraged trading to maximize potential returns.
Hot Topics
Will the 'tariff stick' strike again? Will the market remain 'reactive'?
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome
牛牛課堂
Oct 13 18:05
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?